Table 3. . Therapies used prior to, concurrent with or after T-VEC.†.
| Received another therapy prior to T-VEC, n (%)‡ | Total (N = 76) | Received another therapy concurrent with T-VEC, n (%) | Total (N = 76) | Received another therapy after T-VEC, n (%) | Total (N = 76) |
|---|---|---|---|---|---|
| Ipilimumab | 19 (25.0) | T-VEC + pembrolizumab | 8 (10.5) | Pembrolizumab | 8 (10.5) |
| Clinical trial for melanoma | 15 (19.7) | T-VEC + radiation | 4 (5.3) | Radiation | 3 (3.9) |
| Pembrolizumab | 14 (18.4) | T-VEC + nivolumab | 3 (3.9) | Dabrafenib | 2 (2.6) |
| Radiation | 14 (18.4) | T-VEC + ipilimumab + nivolumab | 2 (2.6) | Ipilimumab | 2 (2.6) |
| Melphalan§ | 11 (14.5) | T-VEC + ipilimumab | 1 (1.3) | Ipilimumab + nivolumab | 2 (2.6) |
| Interferon¶ | 10 (13.2) | T-VEC + vemurafenib | (1.3) | Trametinib | 2 (2.6) |
| Nivolumab | 6 (7.9) | T-VEC + vemurafenib + dabrafenib | 1 (1.3) | Vemurafenib + dabrafenib | 2 (2.6) |
| Interleukin-2# | 5 (6.6) | Clinical trial for melanoma | 1 (1.3) | ||
| Temozolomide | 4 (5.3) | Cisplatin + vinblastine | 1 (1.3) | ||
| Ipilimumab + nivolumab | 3 (3.9) | Cobimetinib + vemurafenib | 1 (1.3) | ||
| Dabrafenib | 2 (2.6) | Dabrafenib + trametinib | 1 (1.3) | ||
| Dabrafenib + trametinib | 2 (2.6) | Larotrectinib | 1 (1.3) | ||
| GM-CSF | 2 (2.6) | Vemurafenib | 1 (1.3) | ||
| Carboplatin + docetaxel | 1 (1.3) | Vemurafenib + cobimetinib | 1 (1.3) | ||
| Carboplatin + nab-paclitaxel | 1 (1.3) | ||||
| Carboplatin + paclitaxel | 1 (1.3) | ||||
| Cisplatin + dacarbazine + vinblastine | 1 (1.3) | ||||
| Cisplatin + vinblastine + temozolomide | 1 (1.3) | ||||
| Dacarbazine | 1 (1.3) | ||||
| Peginterferon alpha-2b | 1 (1.3) | ||||
| Topical imiquimod | 1 (1.3) | ||||
| Vemurafenib | 1 (1.3) | ||||
| Vemurafenib + dabrafenib | 1 (1.3) | ||||
| Vemurafenib + temozolomide | 1 (1.3) | ||||
| Treated with T-VEC only, n (%) | Total (N = 76) | ||||
| T-VEC†† | 17 (22.4) |
Patients may have received more than one other type of therapy before, concurrent with, or after T-VEC.
The subcategories within the melphalan, interferon and IL-2 categories are not mutually exclusive. Subjects are only included once within each subcategory.
Melphalan includes melphalan, melphalan + actinomycin-d, right leg hyperthermic isolated limb perfusion (melphalan) and isolated limb infusion with melphalan + dactinomycin.
Interferon includes adjuvant interferon, adjuvant interferon (systemic), high-dose interferon, interferon, intralesional injection with interferon-α and systemic interferon.
Interleukin-2 includes intralesional injection with Interleukin-2 and high-dose Interleukin-2.
No record of patients receiving other antineoplastic treatment before, concurrent with or after T-VEC.
GM-CSF: Granulocyte macrophage colony-stimulating factor; T-VEC: Talimogene laherparepvec.